Written by the Nuvirox Research Team
- The body's endogenous melatonin production during peak nighttime secretion is approximately 0.1–0.9 mg per day. A 300 mcg (0.3 mg) supplement dose falls within this physiological range—making it a "replacement-level" dose rather than a pharmacological one.
- MIT research by Zhdanova and colleagues (1995, 1996) demonstrated that 0.3–1 mg oral doses facilitated sleep onset as effectively as higher doses in controlled settings, without altering sleep architecture or producing next-morning impairment.
- Despite this evidence, most OTC melatonin products in the US contain 5–10 mg—10 to 30 times the physiological range—because DSHEA supplement classification creates no incentive to match doses to clinical evidence.
Short answer: 300 mcg (0.3 mg) of melatonin is the closest to a physiological dose, is supported by human trial evidence for sleep onset, and avoids the circadian disruption and next-morning grogginess associated with the 5–10 mg doses that dominate pharmacy shelves. The mismatch between what the evidence supports and what the supplement market sells is one of the clearest examples of how dietary supplement regulation in the United States diverges from clinical pharmacology.
What is a "physiological dose" of melatonin and why does it matter?
The human pineal gland produces approximately 0.1–0.9 mg of melatonin per day under normal conditions. This production is not uniform—it is sharply nocturnal, with plasma melatonin levels remaining very low (approximately 10 pg/mL) during waking hours and rising to peak levels of 80–200 pg/mL during the nighttime hours between 2–4am in most adults. The total daily production across this secretion pattern is what gives us the 0.1–0.9 mg estimate.
A "physiological dose" is one that raises plasma melatonin to concentrations within this naturally occurring nighttime range, rather than dramatically exceeding it. A 300 mcg (0.3 mg) oral dose of melatonin—when administered in the evening to someone whose endogenous melatonin is already beginning to rise—produces plasma concentrations in the range of normal physiological nocturnal levels. This is categorically different from a 10 mg dose, which produces plasma melatonin concentrations roughly 200 times higher than normal nighttime peaks. A 50 mg dose—available in some US products—produces concentrations approximately 1,600 times the physiological nocturnal level.
Why does this distinction matter? Two reasons. First, the circadian system has a dose-response relationship with melatonin: there is evidence that very high melatonin concentrations can paradoxically disrupt the melatonin phase-response curve rather than optimizing it. Research by Lewy and colleagues found that physiological doses (0.5 mg) may achieve circadian entrainment effects that pharmacological doses (20 mg) do not, in studies of free-running circadian rhythms in blind individuals. Second, excess melatonin that dramatically overshoots the physiological range remains biologically active hours after administration, contributing to next-morning grogginess and potentially suppressing the body's own melatonin production the following night.
What human studies actually show about 300 mcg melatonin
Zhdanova et al. (1995) — MIT, Clinical Pharmacology & Therapeutics: Irina Zhdanova and Richard Wurtman's group at MIT published what became one of the most-cited early trials on low-dose melatonin. They demonstrated that low oral doses of melatonin given in the evening raised blood melatonin concentrations to those normally occurring nocturnally and facilitated sleep onset—without altering sleep architecture. (DOI: 10.1016/0009-9236(95)90040-3.) Their work established the physiological framing: the goal is to restore a nocturnal melatonin signal, not to flood the system with pharmacological levels.
Zhdanova et al. (1996) — Sleep journal, MIT: This crossover trial in 12 young healthy volunteers gave 0.3 mg or 1.0 mg melatonin (or placebo) at 2100 hours, 2–4 hours before habitual bedtime, with polysomnographic sleep recording. Both the 0.3 mg and 1.0 mg doses significantly facilitated sleep onset. The 0.3 mg dose was adequate—no meaningful additional benefit from tripling the dose to 1.0 mg was detected in sleep latency outcomes. (PMID: 8843534.)
The dose-response meta-analysis (Journal of Pineal Research, 2024; DOI: 10.1111/jpi.12985): A systematic review and dose-response meta-analysis of RCTs on melatonin dose and timing confirmed that 0.3 mg is the minimum efficacious single dose of melatonin for sleep onset, corresponding to a peak plasma concentration of approximately 300 pg/mL. Doses above this produce diminishing additional returns on sleep latency at the population level, while increasing the risk of next-morning sedation and circadian disruption.
The honest counterweight — when higher doses showed larger effects: The 2013 PLOS ONE meta-analysis of 19 RCTs (PMCID: PMC3656905) found that trials with longer duration and higher doses of melatonin showed greater effects on decreasing sleep latency and increasing total sleep time. This is the clearest argument that higher doses are not categorically inferior—and at 5 mg specifically, the Cochrane jet lag review found faster sleep onset compared to 0.5 mg. The nuance is context-dependent: for circadian phase adjustment (jet lag, shift work), the higher dose may offer more robust phase-shifting; for simple sleep onset support in individuals with intact circadian function, 0.3–1 mg appears sufficient.
Why do OTC products contain 5–10 mg if 0.3 mg is sufficient?
This is a legitimate question with an unsatisfying but honest answer: because the supplement market has no regulatory incentive to match dose to evidence. Under DSHEA, manufacturers are not required to demonstrate efficacy before sale, and there is no regulatory ceiling on melatonin doses in dietary supplements. Higher doses look more impressive on a label. Consumers who expect sleep supplements to work like pharmaceuticals often equate higher doses with stronger effects—a pharmacological intuition that is reasonable for many drug classes but breaks down for melatonin, where the mechanism is circadian signaling rather than dose-dependent CNS depression.
Additionally, because oral melatonin bioavailability varies 10- to 30-fold between individuals (some people absorb 10% of a dose, others 56%), manufacturers may reason that a high dose hedges against low-absorbers—which is partially defensible. But it also means high-absorbers consistently receive pharmacological overdoses relative to the physiological range, which is why next-morning grogginess is such a common melatonin complaint. The 300 mcg dose does not hedge this risk to the same extent, but it does serve the population of people with normal-to-high absorption more appropriately.
Who is 300 mcg melatonin most appropriate for?
The low-dose approach is best suited to people who are melatonin-sensitive, who have experienced next-morning grogginess with standard doses, or who are trying melatonin for the first time. It is also the most appropriate dose for those using melatonin primarily as a circadian signal—to advance the clock slightly, support sleep onset at a consistent time, or manage mild jet lag—rather than for sedation. For jet lag specifically, the Cochrane review found 0.5–5 mg effective, with 5 mg producing modestly faster sleep onset than 0.5 mg, so 300 mcg may slightly underperform at the upper end of jet lag use. See our melatonin for jet lag article for the specific dose context there.
The low-dose approach is also appropriate for people concerned about suppressing endogenous melatonin production. While the evidence on this is limited, theoretical concern exists that chronically high exogenous melatonin could downregulate the pineal gland's own production over time—an effect more likely to be relevant at pharmacological doses than physiological ones. This remains an area requiring more long-term human study.
What 300 mcg melatonin won't do
A 300 mcg dose will not produce a strong sedative effect—because melatonin has no meaningful sedative mechanism regardless of dose. If you expect to feel "knocked out," you will be disappointed by 0.3 mg and you would also be disappointed by 10 mg if you understood what melatonin actually does. Low-dose melatonin is not appropriate for severe or chronic primary insomnia driven by anxiety, hyperarousal, sleep apnea, or mood disorders. And as with all melatonin, timing matters more than dose for achieving the circadian effect: a 0.3 mg dose taken 60–90 minutes before desired sleep time is more effective than a larger dose taken at the wrong circadian phase. See a doctor if sleep problems persist beyond 3–4 weeks or significantly impair daytime function despite consistent sleep hygiene and supplementation attempts.
Zhdanova et al. (1996) · Sleep · PMID: 8843534
Design: Randomized, double-blind, placebo-controlled crossover · n: 12 healthy young adults · Duration: Single night per condition · Doses: 0.3 mg or 1.0 mg oral melatonin given at 2100 hrs (2–4 hr before habitual bedtime) · Outcome: Both doses significantly reduced polysomnographically assessed sleep onset latency vs placebo, without altering sleep architecture or next-morning performance · Counterweight: Small single-night crossover; healthy volunteers without insomnia; cannot be generalized to chronic insomnia populations.
Frequently asked questions about melatonin 300 mcg
Is 300 mcg melatonin enough to help me sleep?
For many people, yes—particularly for sleep onset support and circadian timing. The Zhdanova trials demonstrated significant reductions in sleep latency with 0.3 mg in healthy adults. For more severe sleep onset delays, jet lag, or shift work, you may find 1–3 mg more reliably effective. The honest answer is that dose-response varies between individuals; starting at 0.3 mg and adjusting is more evidence-consistent than starting at 10 mg.
Why can't I find 300 mcg melatonin in stores?
Products in the 0.3 mg range exist but are less common than 3–10 mg products. Some brands sell 0.5 mg or 1 mg products as "low dose" options. You can also cut higher-dose tablets; a 1.5 mg tablet cut in thirds yields approximately 0.5 mg per piece, which is close to the physiological range. Quality and consistency of splitting varies, but for melatonin at low doses, this is a practical option.
Does melatonin 300 mcg work for jet lag?
It can, but the Cochrane jet lag review found 5 mg produced faster sleep onset than 0.5 mg (while both were effective for reducing jet lag overall). For jet lag specifically, 0.5–1 mg is likely near the lower bound of reliable effect. A dose of 1–3 mg may be a better sweet spot for jet lag—below the overshooting range while still above the minimum effective threshold. See our article on melatonin for jet lag for the full dose-timing protocol.
Will I feel any different on 300 mcg versus 5 mg melatonin?
Subjectively, many people report less next-morning grogginess with low doses. The acute sedative effect is also milder—which is pharmacologically correct (melatonin is a timing hormone, not a sedative) but may disappoint people expecting a sleep drug experience. People who found high-dose melatonin groggy or who noticed it made their sleep feel flat or unrefreshed may find the low-dose experience substantially more natural.
How should I take melatonin 300 mcg?
Take it 30–90 minutes before your intended sleep time. Unlike the "just before bed" framing on most OTC products, melatonin works best when given enough time to adjust circadian signaling before you need to actually be asleep. For sleep onset support, 60 minutes before bed is a reasonable starting point. For more on timing, see our guide to melatonin dosage.
FROM NUVIROX
Why we formulated Sleep+ Restore
Sleep+ Restore contains 10 mg melatonin—above the 0.3 mg minimum effective threshold discussed in this article—combined with a 905 mg Sleep Formula Proprietary Blend including L-Tryptophan, L-Theanine, Ashwagandha, GABA, 5-HTP, Passion Flower, Chamomile, and Lemon Balm, plus Vitamin B6, Magnesium, and Calcium. The multi-ingredient formula is designed to address sleep onset and quality through multiple mechanisms alongside melatonin's circadian signaling role.
Backed by our 60-day money-back guarantee—long enough to actually evaluate it the way the research says you should.
Learn more about Sleep+ Restore →The bottom line
The case for 300 mcg melatonin is rooted in basic pharmacology and validated by controlled human trials: a physiological-range dose raises plasma melatonin to normal nocturnal levels, facilitates sleep onset, and avoids the circadian disruption and morning grogginess that come with 10–30 times that amount. The fact that US pharmacy shelves are dominated by 5–10 mg products is a function of supplement market dynamics, not clinical evidence. If you haven't tried low-dose melatonin, the MIT research going back to 1995 provides a genuine scientific rationale to start there rather than at the product-aisle default. For the broader evidence context on what melatonin does for sleep across dose ranges, see our foundational article on does melatonin work for sleep, and for how this dose compares to what you'd find in a standard OTC product, our melatonin over the counter article addresses the regulatory backdrop behind why those products are dosed the way they are.
References
- Zhdanova IV, Wurtman RJ, Lynch HJ, et al. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther. 1995;57(5):552-558. DOI: 10.1016/0009-9236(95)90040-3.
- Zhdanova IV, Wurtman RJ, Morabito C, et al. Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep. 1996;19(5):423-431. PMID: 8843534.
- Vural EMS et al. Optimizing the time and dose of melatonin as a sleep-promoting drug: a systematic review of RCTs and dose-response meta-analysis. J Pineal Res. 2014;56(4):385-396. DOI: 10.1111/jpi.12985.
- Lewy AJ, Emens JS, Sack RL, et al. Low, but not high, doses of melatonin entrained a free-running blind person with a long circadian period. Chronobiol Int. 2002;19(3):649-658.
- Waldhauser F et al. Variable bioavailability of oral melatonin. N Engl J Med. 1997;336(14):1028. DOI: 10.1056/NEJM199704033361418.
- DeMuro RL et al. The absolute bioavailability of oral melatonin. J Clin Pharmacol. 2000;40(7):781-784. PMID: 10883420.
- Ferracioli-Oda E et al. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLOS ONE. 2013;8(5):e63773. PMCID: PMC3656905.
- Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev. 2002;(2):CD001520. PMCID: PMC8958662.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.